VivoSeq
Other

Pneumococcal Vaccines

3

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Pneumococcal Vaccines is an early-stage landscape with 3 programs across 5 companies. The most active players are Merck & Co., Novartis, Eli Lilly. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Pfizer logo

Pfizer

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 33

31-Valent Pneumococcal Conjugate Vaccine

Vaxcyte, Inc.

PCV20

Merck & Co.

Seasonal Influenza Vaccine

Novartis

Approved
No programs

Analysis

Trial Status

14

clinical trials

Completed9 · 64%
Active, not recruiting2 · 14%
Withdrawn1 · 7%
Recruiting1 · 7%
Unknown status1 · 7%

Clinical Trials

Trial Activity

14 trials

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15
Recruiting·UUniversity of Oxford·Phase 4·NCT06731374·106 enrolled
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older
Active, not recruiting·VVaxcyte, Inc.·Phase 3·NCT07365826·1,390 enrolled
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination
Active, not recruiting·VVaxcyte, Inc.·Phase 3·NCT07425392·752 enrolled
Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age
Completed·Pfizer logoPfizer·Phase 1·NCT03642847·104 enrolled
Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines
Completed·TThe Jackson Laboratory·Phase 4·NCT03104075·40 enrolled
Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.
Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00148824·212 enrolled
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life
Completed·MMenzies School of Health Research·Phase 4·NCT01735084·261 enrolled
Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
Completed·WWestat·Phase 2·NCT02717494·347 enrolled
Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)
Completed·EEpicentre·Phase 4·NCT05175014·44,618 enrolled
Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines
Completed·UUniversity of Oxford·Phase 3·NCT01432158·4 enrolled
Pneumococcal Vaccines Early and in Combination
Completed·MMenzies School of Health Research·Phase 4·NCT01174849·425 enrolled
Study of Two Investigational Pneumococcal Vaccines in Healthy Adults
Completed·Sanofi logoSanofi·Phase 1·NCT01444339·131 enrolled
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
Withdrawn·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01443117
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
Unknown status·SSungkyunkwan University·N/A·NCT04551248·1,000,000 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)